These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 33273652)

  • 1. Soluble VCAM-1 promotes gemcitabine resistance via macrophage infiltration and predicts therapeutic response in pancreatic cancer.
    Takahashi R; Ijichi H; Sano M; Miyabayashi K; Mohri D; Kim J; Kimura G; Nakatsuka T; Fujiwara H; Yamamoto K; Kudo Y; Tanaka Y; Tateishi K; Nakai Y; Morishita Y; Soma K; Takeda N; Moses HL; Isayama H; Koike K
    Sci Rep; 2020 Dec; 10(1):21194. PubMed ID: 33273652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
    Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z
    Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase.
    Weizman N; Krelin Y; Shabtay-Orbach A; Amit M; Binenbaum Y; Wong RJ; Gil Z
    Oncogene; 2014 Jul; 33(29):3812-9. PubMed ID: 23995783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue Transglutaminase Activates Cancer-Associated Fibroblasts and Contributes to Gemcitabine Resistance in Pancreatic Cancer.
    Lee J; Yakubov B; Ivan C; Jones DR; Caperell-Grant A; Fishel M; Cardenas H; Matei D
    Neoplasia; 2016 Nov; 18(11):689-698. PubMed ID: 27792935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1α Pathway.
    Xu F; Huang M; Chen Q; Niu Y; Hu Y; Hu P; Chen D; He C; Huang K; Zeng Z; Tang J; Wang F; Zhao Y; Wang C; Zhao G
    Cancer Res; 2021 Nov; 81(22):5678-5691. PubMed ID: 34593522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer.
    Liu Y; Li F; Gao F; Xing L; Qin P; Liang X; Zhang J; Qiao X; Lin L; Zhao Q; Du L
    Tumour Biol; 2016 Nov; 37(11):15283-15291. PubMed ID: 27696296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine suppresses malignant ascites of human pancreatic cancer: correlation with VEGF expression in ascites.
    Kuwahara K; Sasaki T; Kobayashi K; Noma B; Serikawa M; Iiboshi T; Miyata H; Kuwada Y; Murakami M; Yamasaki S; Kariya K; Morinaka K; Chayama K
    Oncol Rep; 2004 Jan; 11(1):73-80. PubMed ID: 14654905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
    Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
    Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model.
    Brandes F; Schmidt K; Wagner C; Redekopf J; Schlitt HJ; Geissler EK; Lang SA
    BMC Cancer; 2015 Feb; 15():71. PubMed ID: 25884642
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Tadros S; Shukla SK; King RJ; Gunda V; Vernucci E; Abrego J; Chaika NV; Yu F; Lazenby AJ; Berim L; Grem J; Sasson AR; Singh PK
    Cancer Res; 2017 Oct; 77(20):5503-5517. PubMed ID: 28811332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemcitabine enhances cell invasion via activating HAb18G/CD147-EGFR-pSTAT3 signaling.
    Xu BQ; Fu ZG; Meng Y; Wu XQ; Wu B; Xu L; Jiang JL; Li L; Chen ZN
    Oncotarget; 2016 Sep; 7(38):62177-62193. PubMed ID: 27556697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bmi1 inhibition enhances the sensitivity of pancreatic cancer cells to gemcitabine.
    Yin T; Zhang Z; Cao B; Duan Q; Shi P; Zhao H; Camara SN; Shen Q; Wang C
    Oncotarget; 2016 Jun; 7(24):37192-37204. PubMed ID: 27177084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2.
    Dangi-Garimella S; Krantz SB; Barron MR; Shields MA; Heiferman MJ; Grippo PJ; Bentrem DJ; Munshi HG
    Cancer Res; 2011 Feb; 71(3):1019-28. PubMed ID: 21148071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancreatic Microtumors: A Novel 3D Ex Vivo Testing Platform.
    Goodwin ML; Urs SK; Simeone DM
    Methods Mol Biol; 2019; 1882():73-80. PubMed ID: 30378045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts.
    Waters JA; Matos J; Yip-Schneider M; Aguilar-Saavedra JR; Crean CD; Beane JD; Dumas RP; Suvannasankha A; Schmidt CM
    Surgery; 2015 Oct; 158(4):881-8; discussion 888-9. PubMed ID: 26209568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atorvastatin (Lipitor) attenuates the effects of aspirin on pancreatic cancerogenesis and the chemotherapeutic efficacy of gemcitabine on pancreatic cancer by promoting M2 polarized tumor associated macrophages.
    Liu Q; Li Y; Niu Z; Zong Y; Wang M; Yao L; Lu Z; Liao Q; Zhao Y
    J Exp Clin Cancer Res; 2016 Feb; 35():33. PubMed ID: 26879926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
    Liu M; Zhang Y; Yang J; Cui X; Zhou Z; Zhan H; Ding K; Tian X; Yang Z; Fung KA; Edil BH; Postier RG; Bronze MS; Fernandez-Zapico ME; Stemmler MP; Brabletz T; Li YP; Houchen CW; Li M
    Gastroenterology; 2020 Feb; 158(3):679-692.e1. PubMed ID: 31711924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
    McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
    Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine-Induced TIMP1 Attenuates Therapy Response and Promotes Tumor Growth and Liver Metastasis in Pancreatic Cancer.
    D'Costa Z; Jones K; Azad A; van Stiphout R; Lim SY; Gomes AL; Kinchesh P; Smart SC; Gillies McKenna W; Buffa FM; Sansom OJ; Muschel RJ; O'Neill E; Fokas E
    Cancer Res; 2017 Nov; 77(21):5952-5962. PubMed ID: 28765154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
    Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
    Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.